Ethical Pharmaceuticals

Since we first developed penicillin in 1946, Meiji has been conducting R&D and has launched innovative products, both in Japan and overseas. While focusing mainly on infectious diseases and CNS (central nervous system disorders), our R&D is also venturing into other fields such as oncology, immunology and biologics in order to develop new drugs to fulfill unmet needs of patients worldwide. By continually improving our R&D process with innovation, Meiji brings high-value and high-quality drugs to market quickly and on a timely basis, including new chemical entities and biosimilars.

specialty & generic

Infectious Disease
Viruses, etc.
New Fields
Biologics, etc.

R&D Facilities

Pharmaceutical Research Center

Pharmaceutical Research Center

760 Morooka-cho Kohoku-ku, Yokohama-shi Kanagawa-ken 222-8567 Japan

CMC Research Laboratories

CMC Research Laboratories

760 Morooka-cho Kohoku-ku,Yokohama-shi Kanagawa-ken 222-8567 Japan

Bioscience Laboratories

Bioscience Laboratories

788 Kayama Odawara-shi Kanazawa-ken
250-0852 Japan

Product Pipeline

The following table describes our complete product pipeline for all pharmaceuticals under clinical development in Phase I or later.

As of August 2017
Stage Name Type Efficacy Classification Notes
Approval SME3110
Oral Selective serotonin
reuptake inhibitor (SSRI)
(Dosage & administration
in Pediatric OCD)
Approved on July 3, 2017
Oral Antipsychotic In-license: RaQualia Pharma Inc.
Oral Anti-Parkinson's Disease In-license: Newron Pharmaceuticals S.p.A.
Licenced out to Eisai Co., LTD.(Japan)
PII (International collaborative clinical trial) SP-02L
Injection Relapsed and refractory peripheral T-cell lymphoma (PTCL) In-license: Solasia Pharma K.K.
Oral Fibromyalgia treatment
(Additional indications)
In-license: MSD K.K.
PII (Overseas) ME1111 Topical Antionychomycosis Meiji Seika Pharma Co., Ltd.
PI DMB-3111 Injection Breast Cancer/Gastric Cancer (Biosimilar) Co-development: Dong-A Socio Holdings Co., Ltd. (Korea)
DMB-3113 Injection Rheumatoid Arthritis/TNFa inhibitor Co-development:Dong-A ST (Korea)
Licenced out to Gedeon Richter Plc.(Hungary)
OP0595 Injection β-lactamase inhibitor Meiji Seika Pharma Co., Ltd.
Licensed out to F. Hoffman-La Roche (Switzerland)
PI (Overseas) ME1100
Inhalation Hospital Acquired Bacterial Pneumonia / Ventilator Associated Bacterial Pneumonia treatment
Meiji Seika Pharma Co., Ltd.

Agricultural Chemicals and Veterinary Drugs

Cultivating wellness in all aspects of life.


Meiji continues to develop new agrochemical candidates including insecticides, herbicides and fungicides in order to ensure a stable supply of crops and help increase food production worldwide. We are conducting efficacy field trials for several promising candidates that we hope to eventually register.
We reached a licensing agreement in 2010 with BASF SE of Germany for overseas rights to a novel agricultural insecticide. This next-generation insecticide is eco friendly and safer than existing types, and is slated for worldwide registration. Other overseas activities include a 2013 agreement with Dow AgroSciences LLC of the US for co-development and commercialization of an agrochemical fungicide featuring a novel mechanism of action against pathogens that cause wheat diseases.

Animal health

Our lineup of veterinary drugs for companion animals and livestock continues to grow, with innovative products continually being developed, tested and released.

R&D Facilities

Pharmaceutical Research Center

Bioscience Laboratories

788 Kayama Odawara-shi Kanagawa-ken
250-0852 Japan

Pharmaceutical Research Center

Agricultural & Veterinary
Research Laboratories

760 Morooka-cho Kohoku-ku, Yokohama-shi Kanagawa-ken 222-8567 Japan

Product pipeline

As of May 2017